Entrada Therapeutics Inc (TRDA)
18.05
+0.12
(+0.67%)
USD |
NASDAQ |
Nov 21, 16:00
18.08
+0.02
(+0.14%)
After-Hours: 20:00
Entrada Therapeutics Profit Margin (Quarterly): -71.70% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -71.70% |
| June 30, 2024 | 58.11% |
| March 31, 2024 | 39.74% |
| December 31, 2023 | -22.81% |
| Date | Value |
|---|---|
| September 30, 2023 | 81.08% |
| June 30, 2023 | -142.7% |
| March 31, 2023 | -26.42% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-142.7%
Minimum
Jun 2023
81.08%
Maximum
Sep 2023
-12.10%
Average
-22.81%
Median
Dec 2023
Profit Margin (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 34.10% |
| Vertex Pharmaceuticals Inc | 37.71% |
| Assembly Biosciences Inc | -140.4% |
| Sarepta Therapeutics Inc | 7.19% |
| Regenxbio Inc | -246.3% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 17.06% |
| Return on Assets | 10.56% |
| Return on Invested Capital | 17.06% |
| Operating Margin (Quarterly) | -110.7% |
| Return on Net Operating Assets | 47.77% |